OncoMatch/Clinical Trials/NCT03899155

Pan Tumor Rollover Study

Is NCT03899155 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for cancer.

Phase 2RecruitingBristol-Myers SquibbNCT03899155Data as of May 2026

Treatment: Nivolumab · Ipilimumab · Cabozantinib · Trametinib · Relatlimab · Nivolumab + Relatlimab · Capecitabine · Bevacizumab · Temozolomide · Rucaparib · Daratumumab · Regorafinib · Leucovorin · Fluorouracil · Oxaliplatin · Enzalutamide · Sunitinib · Pemetrexed · Pembrolizumab — Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.

Check if I qualify

Eligibility summary

For patients with cancer.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

US trial sites

Local Institution - 0220 · Huntsville, Alabama
University of Arizona College of Medicine · Tucson, Arizona
Innovative Clinical Research Institute · Lynwood, California
Local Institution · San Francisco, California
Local Institution - 0099 · San Francisco, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify